Literature DB >> 17427378

Breed associations for canine exocrine pancreatic insufficiency.

Daniel J Batchelor1, Peter-John M Noble, Peter J Cripps, Rebecca H Taylor, Lynn McLean, Marion A Leibl, Alexander J German.   

Abstract

BACKGROUND: Knowledge of breed associations is valuable to clinicians and researchers investigating diseases with a genetic basis. HYPOTHESIS: Among symptomatic dogs tested for exocrine pancreatic insufficiency (EPI) by canine trypsin-like immunoreactivity (cTLI) assay, EPI is common in certain breeds and rare in others. Some breeds may be overrepresented or underrepresented in the population of dogs with EPI. Pathogenesis of EPI may be different among breeds. ANIMALS: Client-owned dogs with clinical signs, tested for EPI by radioimmunoassay of serum cTLI, were used.
METHODS: In this retrospective study, results of 13,069 cTLI assays were reviewed.
RESULTS: An association with EPI was found in Chows, Cavalier King Charles Spaniels (CKCS), Rough-Coated Collies (RCC), and German Shepherd Dogs (GSD) (all P < .001). Chows (median, 16 months) were younger at diagnosis than CKCS (median, 72 months, P < .001), but not significantly different from GSD (median, 36 months, P = .10) or RCC (median, 36 months, P = .16). GSD (P < .001) and RCC (P = .015) were younger at diagnosis than CKCS. Boxers (P < .001), Golden Retrievers (P < .001), Labrador Retrievers (P < .001), Rottweilers (P = .022), and Weimaraners (P = .002) were underrepresented in the population with EPI. CONCLUSIONS AND CLINICAL IMPLICATIONS: An association with EPI in Chows has not previously been reported. In breeds with early-onset EPI, immune-mediated mechanisms are possible or the disease may be congenital. When EPI manifests later, as in CKCS, pathogenesis is likely different (eg, secondary to chronic pancreatitis). Underrepresentation of certain breeds among dogs with EPI has not previously been recognized and may imply the existence of breed-specific mechanisms that protect pancreatic tissue from injury.

Entities:  

Mesh:

Year:  2007        PMID: 17427378     DOI: 10.1892/0891-6640(2007)21[207:bafcep]2.0.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  6 in total

1.  Alleles of the major histocompatibility complex play a role in the pathogenesis of pancreatic acinar atrophy in dogs.

Authors:  Kate L Tsai; Alison N Starr-Moss; Gopalakrishnan M Venkataraman; Christopher Robinson; Lorna J Kennedy; Jörg M Steiner; Leigh Anne Clark
Journal:  Immunogenetics       Date:  2013-04-21       Impact factor: 2.846

2.  Prevalence of disorders recorded in Cavalier King Charles Spaniels attending primary-care veterinary practices in England.

Authors:  Jennifer F Summers; Dan G O'Neill; David B Church; Peter C Thomson; Paul D McGreevy; David C Brodbelt
Journal:  Canine Genet Epidemiol       Date:  2015-04-18

3.  Demography and disorders of German Shepherd Dogs under primary veterinary care in the UK.

Authors:  Dan G O'Neill; Noel R Coulson; David B Church; Dave C Brodbelt
Journal:  Canine Genet Epidemiol       Date:  2017-07-28

4.  Genomic association and further characterisation of faecal immunoglobulin A deficiency in German Shepherd dogs.

Authors:  Niels Grützner; Romy M Heilmann; Ursula Tress; Iain R Peters; Jan S Suchodolski; Jörg M Steiner
Journal:  Vet Med Sci       Date:  2021-08-14

5.  A blinded randomised controlled trial to determine the effect of enteric coating on enzyme treatment for canine exocrine pancreatic efficiency.

Authors:  Aran Mas; Peter-John M Noble; Peter J Cripps; Daniel J Batchelor; Peter Graham; Alexander J German
Journal:  BMC Vet Res       Date:  2012-07-28       Impact factor: 2.741

6.  Randomized placebo controlled clinical trial of an enteric coated micro-pelleted formulation of a pancreatic enzyme supplement in dogs with exocrine pancreatic insufficiency.

Authors:  Joseph Cyrus Parambeth; Geoffrey T Fosgate; Jan S Suchodolski; Jonathan A Lidbury; Jörg M Steiner
Journal:  J Vet Intern Med       Date:  2018-09-17       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.